Skip to main content
SpringerLink
Log in

Afatinib/erlotinib/gefitinib

Various toxicities: 22 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sakata Y, et al. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. Asia-Pacific Journal of Clinical Oncology 16: e113-e117, No. 2, Apr 2020. Available from: URL: http://doi.org/10.1111/ajco.13103

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/erlotinib/gefitinib. Reactions Weekly 1802, 16 (2020). https://doi.org/10.1007/s40278-020-77934-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-77934-9

Search

Navigation